Which testosterone laboratory tests (total testosterone, free testosterone, etc.) should be ordered for a female patient using a Mirena levonorgestrel intrauterine device?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Best Testosterone Labs for Female Patients with Mirena IUD

For female patients with a Mirena IUD, order total testosterone and free testosterone (preferably by mass spectrometry, or calculated free testosterone if unavailable) as first-line tests, with SHBG to enable calculation of free testosterone or free androgen index (FAI). 1

Recommended Testing Algorithm

First-Line Tests

  • Total testosterone (TT): Essential baseline measurement
  • Free testosterone (FT): Most accurate when measured by mass spectrometry; alternatively use calculated free testosterone (cFT)
  • SHBG: Required to calculate free testosterone or FAI when direct free testosterone measurement is unavailable

The 2025 International PCOS Guidelines meta-analysis establishes that total and free testosterone provide the highest diagnostic accuracy for biochemical hyperandrogenism in women, with pooled sensitivities of 74% and 89% respectively, and specificities of 86% and 83% 1. Where mass spectrometry is unavailable, FAI (calculated as total testosterone/SHBG × 100) serves as an acceptable alternative 1.

Important Consideration for Mirena Users

The levonorgestrel in Mirena IUD decreases SHBG levels 2. This is clinically significant because lower SHBG increases the proportion of free (bioavailable) testosterone. When SHBG is reduced, total testosterone alone may underestimate androgenic activity, making free testosterone or FAI measurements particularly important in this population 3, 4.

Research demonstrates that levonorgestrel-containing IUDs reduce mean SHBG from approximately 62 nmol/L to 42 nmol/L, though this difference may not always reach statistical significance 2. The correlation between levonorgestrel levels and SHBG suppression is highly significant (r = 0.89) 2.

Second-Line Tests (If Initial Tests Normal but Clinical Suspicion Persists)

If total and free testosterone are normal but hyperandrogenic symptoms persist:

  • Androstenedione (A4): Sensitivity 75%, specificity 71% 1
  • DHEAS: Sensitivity 75%, specificity 67% 1

Note the critical caveat: These second-line androgens have notably poorer specificity than testosterone measurements, meaning more false positives 1.

Methodological Considerations

Preferred Assay Methods

  1. Gold standard: Mass spectrometry (LC-MS/MS or GC-MS) for testosterone measurement 3, 1
  2. Acceptable alternative: Validated immunoassays with extraction and chromatography 3
  3. Avoid: Direct immunoassays without extraction for free testosterone, as these show poor correlation with ultrafiltration methods 5

Pre-analytical Requirements

  • Morning blood sampling (though testosterone variation across menstrual cycle is relatively small compared to overall variability) 6
  • Document menstrual cycle timing if applicable
  • Avoid sampling during use of medications that alter SHBG (thyroid hormones, antiepileptics) 3

Clinical Interpretation Framework

When total testosterone is elevated (≥2× upper limit of normal):

  • Add DHEAS to differentiate adrenal vs. ovarian source 3
  • DHEAS >600 µg/dl (16,000 nmol/L) suggests adrenal adenoma requiring imaging 3

When total testosterone is normal but clinical hyperandrogenism is evident:

  • Free testosterone or FAI becomes critical 3
  • SHBG reduction (from obesity, metabolic syndrome, or levonorgestrel) can mask hyperandrogenism when only total testosterone is measured 3

Common Pitfalls to Avoid

  1. Ordering only total testosterone in Mirena users: The progestin effect on SHBG makes free testosterone assessment essential
  2. Using direct free testosterone immunoassays: These show 2-7 fold discrepancies compared to reference methods 5
  3. Ignoring SHBG context: Total testosterone must be interpreted relative to SHBG binding capacity 3, 4
  4. Relying on salivary testosterone: Poor correlation with plasma free testosterone in women using hormonal contraceptives 7

The evidence strongly supports a systematic approach prioritizing total and free testosterone measurements, with SHBG measurement enabling proper interpretation in the context of levonorgestrel-induced SHBG suppression from the Mirena IUD.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.